NASDAQ:MGTA - Magenta Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.49 -0.43 (-5.43 %)
(As of 12/14/2018 08:05 AM ET)
Previous Close$7.92
Today's Range$7.25 - $8.43
52-Week Range$6.10 - $16.33
Volume145,220 shs
Average Volume53,976 shs
Market Capitalization$262.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTA
Previous Symbol
CUSIPN/A
Phone857-242-0170

Debt

Debt-to-Equity RatioN/A
Current Ratio13.66
Quick Ratio13.66

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees48
Outstanding Shares33,150,000
Market Cap$262.56 million
OptionableNot Optionable

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics Inc (NASDAQ:MGTA) announced its earnings results on Thursday, November, 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.18. View Magenta Therapeutics' Earnings History.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Magenta Therapeutics.

What price target have analysts set for MGTA?

4 analysts have issued twelve-month target prices for Magenta Therapeutics' stock. Their predictions range from $18.00 to $22.00. On average, they expect Magenta Therapeutics' share price to reach $19.3333 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.

What is the consensus analysts' recommendation for Magenta Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.

Has Magenta Therapeutics been receiving favorable news coverage?

Press coverage about MGTA stock has been trending somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Magenta Therapeutics earned a news impact score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of Magenta Therapeutics' key competitors?

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the folowing people:
  • Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 47)
  • Mr. Michael P. Cooke, Chief Scientific Officer (Age 56)
  • Ms. Alison Lawton, Board Advisor (Age 57)
  • Ms. Cindy Driscoll, VP of Fin. & Treasurer (Age 52)
  • Ms. Manisha Pai, VP of Investor Relations & Communications

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

When does Magenta Therapeutics' lock-up period expire?

Magenta Therapeutics' lock-up period expires on Tuesday, December 18th. Magenta Therapeutics had issued 6,666,667 shares in its public offering on June 21st. The total size of the offering was $100,000,005 based on an initial share price of $15.00. After the expiration of Magenta Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FIL Ltd (2.90%), Opaleye Management Inc. (2.19%), Laurion Capital Management LP (0.86%), BlackRock Inc. (0.52%), Vanguard Group Inc (0.44%) and Vanguard Group Inc. (0.44%). Company insiders that own Magenta Therapeutics stock include David Scadden and Jason Gardner. View Institutional Ownership Trends for Magenta Therapeutics.

Which institutional investors are selling Magenta Therapeutics stock?

MGTA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP. View Insider Buying and Selling for Magenta Therapeutics.

Which institutional investors are buying Magenta Therapeutics stock?

MGTA stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., FIL Ltd, BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Bollard Group LLC and Platinum Investment Management Ltd.. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden and Jason Gardner. View Insider Buying and Selling for Magenta Therapeutics.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $7.49.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $262.56 million. Magenta Therapeutics employs 48 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is http://www.magentatx.com.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]


MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel